Cancer Risk Reduction Strategies for Transgender, Non-Binary, and Gender-Diverse People With Hereditary Cancer Syndromes

Presented by:
Julie S. Mak
Search for other papers by Julie S. Mak in
Current site
Google Scholar
PubMed
Close
 MS, MSc, CGC
and
Diego Rodriguez
Search for other papers by Diego Rodriguez in
Current site
Google Scholar
PubMed
Close
 MSN, RN, OCN
Restricted access

Approximately 24 million people in the United States identify as transgender, non-binary, or gender-diverse, and they often face challenges in accessing health care related to education, employment, and economic circumstances. In addition, their gender identity can create other hurdles to receiving appropriate health care, as well as gender dysphoria caused by procedures and preventive cancer screening that do not align with their current gender identity. It is important to consider hereditary risk and gender identity together. Clinicians should engage patients in creating a personalized plan (focusing on genetic risk; age-specific risk; sex assigned at birth and organs present at birth; gender identity; and gender-affirming surgeries and medications) and work with colleagues across medical disciplines to meet the health care needs of this fast-growing patient population.

Disclosures: The presenters have disclosed no relevant financial relationships.

Correspondence: Julie S. Mak, MS, MSc, CGC, UCSF Medical Center, Hereditary Cancer Clinic, 1825 4th Street, 6th Floor, Box 4065, San Francisco, CA 94108. Email: julie.mak@ucsf.edu; and
Diego Rodriguez, MSN, RN, OCN, City of Hope National Medical Center, 1043 Elm Avenue, Suite 104, Long Beach, CA 90813. Email: dierodriguez@coh.org
  • Collapse
  • Expand
  • 1.

    Society of Gynecologic Oncology. Welcoming spaces. Accessed April 5, 2024. Available at: https://www.sgo.org/welcomingspaces/

  • 2.

    de Blok CJM, Wiepjes CM, Nota NM, et al. Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. BMJ 2019;365:l1652.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Sutherland N, Espinel W, Grotzke M, et al. Unanswered questions: hereditary breast and gynecological cancer risk assessment in transgender adolescents and young adults. J Genet Couns 2020;29:625633.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Leone AG, Trapani D, Schabath MB, et al. Cancer in transgender and gender-diverse persons: a review. JAMA Oncol 2023;9:556563.

  • 5.

    Coleman E, Radix AE, Bouman WP, et al. Standards of care for the health of transgender and gender diverse people, version 8. Int J Transgend Health 2022;23(Suppl 1):S1259.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Daly MB, Pal T, AlHilli Z, et al. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 3.2024. Accessed April 5, 2024. To view the most recent version, visit https://www.nccn.org

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Bilash T, Walker LM. Spare parts: navigating ovarian cancer as a transgender man. J Clin Oncol 2022;40:10271029.

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1369 1369 129
PDF Downloads 354 354 9
EPUB Downloads 0 0 0